Sentences with phrase «synuclein at»

Not exact matches

Moreover, the results showed that many effects of alpha - synuclein have been conserved across a billion years of evolution from yeast to human,» said Khurana, former Visiting Scientist at the Whitehead Institute.

Melki, a protein researcher at the Paris - Saclay Institute of Neuroscience, is known for his ability to generate distinct types of alpha - synuclein.

To investigate, scientists at the University of California at San Diego ran supercomputer simulations using 962,757 processor hours to explore myriad possible shapes that alpha - synuclein molecules can take.

In the current study, Lasmézas and her team looked at cell cultures of neurons that were induced to accumulate fibrils made of misfolded α - synuclein, mimicking Lewy bodies in patients with Parkinson's.

Last week, findings presented at the huge annual meeting of the Society for Neuroscience further buttressed the theory that spread of the rogue protein, called α - synuclein, is responsible for the progressive disease, which is marked by tremor, stiff movements, depression, and, ultimately, dementia.

Researchers at the University of Pittsburgh School of Medicine have uncovered a major reason why the Parkinson's - related protein alpha - synuclein, a major constituent of the Lewy bodies that are the pathological hallmark of Parkinson's disease (PD), is toxic to neurons in the brain.

People whose cells make too much alpha - synuclein or make a mutated form of the protein are at high risk of developing PD because of the protein's toxicity, researchers found.

This may allow damaged or degenerating neurons to maintain their function for longer than those who are less efficient at retaining α - synuclein.

Yet if you look at people who develop the clinical syndrome of dementia, especially later in life, yes, they have amyloid in the brain but they also have other pathologic entities — vascular disease; synucleinopathies [insoluble fibrils of the normally soluble protein, alpha - synuclein]; a tauopathy [which is marked by disease - inducing, insoluble tangles of another protein, tau].

Because most cases of Parkinson's disease appear to be at least partially caused by environmental factors such as pesticide exposure, these findings support the approach that targeting α - synuclein could slow or stop the progression of Parkinson's in most people with the disease, said study lead author Jeff Bronstein, a professor of neurology and director of movement disorders at the David Geffen School of Medicine at UCLA.

Knowing the structures of pathological forms of amyloid seeds should help to design small molecules that bind to them and stop them doing damage, says biophysicist Ronald Melki at the Paris - Saclay Institute of Neuroscience, who works on α - synuclein strains.

«Our present approach was to look at this long - distance transmission of alpha - synuclein from the opposite perspective, investigating the possibility that alpha - synuclein may travel from the brain to the gut.»

PRX002: Targeting C - Truncated Alpha - Synuclein When we last reported news from Prothena Corp PLC, their cofounder and CEO Dr. Dale Schenk had recently presented the results of studies using their AS - targeting antibodies at SENS Research Foundation's Rejuvenation Biotechnology 2014 conference.

There are now multiple immunotherapies targeting clearance of alpha - synuclein from the brain in early - stage clinical trials, and multiple trials underway or in the works on the next generation of cell replacement therapies for dopaminergic neurons, including the TRANSEURO trial; the Summit4StemCell initiative, put together by Jeanne Loring — a researcher at The Scripps Research Institute who is exceptionally engaged with turning her research into therapies; a Japanese trial to be run by Jun Takahashi of Kyoto University in Japan (cf. here and here); and a trial centered at Memorial Sloan Kettering Cancer Center headed by cell biologist Lorenz Studer.

PD01A: Promising Animal Efficacy; Initial Human Safety and Hints of Disease Modification At the time of our last post on α - synuclein vaccines, AFFiRiS had published several papers about the AFFITOME immnotherapy discovery platform [8 - 11] and had even begun their first Phase I trial of PD01A, but had kept nearly silent on many of the most elementary aspects of the vaccine.

«We could literally see that squalamine, given orally to the worms, did not allow alpha - synuclein to cluster, and prevented muscular paralysis inside the worms,» says the study's co-senior author, Michael Zasloff, MD, PhD, professor of surgery and pediatrics at Georgetown University School of Medicine and scientific director of the MedStar Georgetown Transplant Institute.

«We could literally see that squalamine, given orally to the worms, did not allow α - synuclein to cluster, and prevented muscular paralysis inside the worms,» says the study's co-senior author, Michael Zasloff, MD, PhD, professor of surgery and pediatrics at Georgetown University School of Medicine and scientific director of the MedStar Georgetown Transplant Institute.

Twenty - two sections of paraffin - embedded tissue were stained for Luxol fast blue, hematoxylin and eosin, Bielschowsky silver, phosphorylated tau (ptau)(AT8), α - synuclein, amyloid - β, and phosphorylated transactive response DNA binding protein 43 kDa (pTDP - 43) using methods described previously.16 In some cases, large coronal slabs of the cerebral hemispheres were also cut at 50 μm on a sledge microtome and stained as free - floating sections using AT8 or CP - 13.16,17